How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,360 results for

Skin Conditions in Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Insulin aspart (Fiasp) - Diabetes Mellitus

2. Scientific discussion 2.1. Problem statement 2.1.1. Disease or condition Chronic hyperglycaemia defines diabetes, and glycaemic control is fundamental to diabetes management. Improvement in long-term glucose control has been demonstrated to reduce the incidence and progression of complications in people with type 1 (T1DM) or type 2 diabetes mellitus (T2DM). Both fasting glycaemia and glycaemic excursions occurring after meals contribute to overall glycaemic burden, a major contributor (...) Insulin aspart (Fiasp) - Diabetes Mellitus 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 10 November 2016 EMA/CHMP/50360/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Fiasp International non-proprietary name: insulin aspart Procedure No. EMEA/H/C/004046/0000 Note Assessment report as adopted

2017 European Medicines Agency - EPARs

22. Islet Transplantation Islet transplantation in patients with Type 1 Diabetes Mellitus

Islet Transplantation Islet transplantation in patients with Type 1 Diabetes Mellitus Technology Assessment Unit of the McGill University Health Centre (MUHC) Islet transplantation in patients with Type 1 Diabetes Mellitus Report number: 66 DATE: 2014/4/18 Report available from http://www.mcgill.ca/tau Report prepared for the Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC) by Xuanqian Xie, Benjamin Rich, Nandini Dendukuri Report requested by Dr. Ewa Sidorowicz (...) , Associate Director of Professional Services, McGill University Health Centre Approved by the Committee of the TAU on May 9, 2014 TAU Committee Andre Bonnici, James Brophy, Nandini Dendukuri, Sandra Dial, Christian Janicki, Patricia Lefebvre, Brenda MacGibbon-Taylor, Gary Pekeles, Guylaine Potvin, Patty O’Connor, Hugh Scott, Gary Stoopler Suggested citation: Xie X, Rich B, Dendukuri N. Islet Transplantation in Patients with Type 1 Diabetes Mellitus. Montreal (Canada): Technology Assessment Unit (TAU

2014 McGill TAU reports

23. Cardiovascular Disease Risk Factors in Youth With Diabetes Mellitus

Cardiovascular Disease Risk Factors in Youth With Diabetes Mellitus Cardiovascular Disease Risk Factors in Youth With Diabetes Mellitus | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use (...) of cookies. Free Access article Share on Jump to Free Access article Cardiovascular Disease Risk Factors in Youth With Diabetes Mellitus A Scientific Statement From the American Heart Association , MD, PhD , MD, PhD, FAHA , MD , MD , MD, MS , MD, PhD , PhD, FAHA , MD, MS , RN, PhD , MD, ScD , PhD, RN, FAHA , and MD, MS MD, MS, FAHAon behalf of the American Heart Association Atherosclerosis, Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young, Council

2014 American Heart Association

24. Lantus (insulin glargine) - diabetes mellitus in children aged 2 to 5 years

: adolescents and children from age 6 years - 25 May 2012 : children aged 2 to 5 years Prescribing and dispensing conditions/ special status List II ATC Classification (2012) A Alimentary tract and metabolism A10 Drugs used in diabetes A10A Insulins and analogues A10AE Insulins and analogues for injection, long-acting A10AE04 Insulin glargine 02 BACKGROUND The Committee assessed the extension of indication granted to LANTUS on 25 May 2012 by the EMA in the “treatment of diabetes mellitus in children aged 2 (...) Lantus (insulin glargine) - diabetes mellitus in children aged 2 to 5 years HAS – Medical, Economic and Public Health Assessment Division 1/12 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 18 December 2013 LANTUS 100 units/ml, solution for injection in a vial B/1 vial of 10 ml (CIP: 34009 359 464 9 2) LANTUS 100 units/ml, solution for injection in cartridge B/5 cartridges of 3 ml (CIP: 34009 354 632 0 3) LANTUS

2014 Haute Autorite de sante

25. Levemir penfill (insulin detemir) - Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above

Levemir penfill (insulin detemir) - Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above HAS - Medical, Economic and Public Health Assessment Division 1/33 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 18 December 2013 LEVEMIR PENFILL 100 IU/ml, solution for injection B/5 cartridges of 3 ml (CIP: 34009 365 118-1) LEVEMIR FLEXPEN 100 IU/ml, solution for injection B/5 pre-filled (...) pens of 3 ml (CIP: 34009 365 119-8) LEVEMIR INNOLET 100 IU/ml, solution for injection B/5 pre-filled pens of 3 ml (CIP: 34009 365 120-6) Applicant: NOVO NORDISK PHARMACEUTIQUE SAS INN insulin detemir ATC Code (2013): A10AE05 (Insulins and analogues for injection, long-acting) Reason for the review Renewal of inclusion List concerned National Health Insurance (French Social Security Code L.162-17) Indication concerned "Treatment of diabetes mellitus in adults, adolescents and children aged 2 years

2014 Haute Autorite de sante

26. Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)

and managed by the CDMC, no patient enrollment will occur at MDACC. All patient recruitment will occur at external sites that are a part of the CPDPC, which are listed in the appended DETECT protocol. The data management systems, auditing, and monitoring effort are supported by the CDMC. Condition or disease Intervention/treatment Pancreatic Cancer Chronic Pancreatitis Diabetes Mellitus Type 3c Other: Data Management and Monitoring Study Design Go to Layout table for study information Study Type (...) Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT) Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study

2018 Clinical Trials

27. Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus Actual Study Start Date : March 7, 2018 Actual Primary Completion Date : December 22, 2018 Actual Study Completion Date : December 22, 2018 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: SAR247799 SAR247799 repeated doses once daily in the morning under fasted condition for 28 days according to a sequential dose design Drug: SAR247799 Pharmaceutical form:Capsule Route (...) Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save

2018 Clinical Trials

28. A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus

. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: MEDI0382 Drug: Placebo Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 20 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment Official Title: A Phase 2a Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics (...) A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2018 Clinical Trials

29. A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.

). Approximately 20 subjects will be enrolled in Part A and approximately 24 subjects in Part B. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: MEDI0382 Drug: Placebo Drug: Liraglutide Phase 2 Detailed Description: This is a 2-part exploratory Phase 2 study. Part A is a randomised, double-blind, placebo-controlled study to evaluate the effect of MEDI0382 administered once daily subcutaneously (SC) for 28 days on hepatic glycogen metabolism in overweight and obese subjects (...) A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save

2018 Clinical Trials

30. A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Subjects With Type 2 Diabetes Mellitus

for details. ClinicalTrials.gov Identifier: NCT03596177 Recruitment Status : Recruiting First Posted : July 23, 2018 Last Update Posted : March 15, 2019 See Sponsor: MedImmune LLC Information provided by (Responsible Party): MedImmune LLC Study Details Study Description Go to Brief Summary: An Exploratory study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Subjects with Type 2 Diabetes Mellitus Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type II (...) A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Subjects With Type 2 Diabetes Mellitus A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2018 Clinical Trials

31. Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus

: August 31, 2018 Last Update Posted : February 28, 2019 See Sponsor: MedImmune LLC Information provided by (Responsible Party): MedImmune LLC Study Details Study Description Go to Brief Summary: To evaluate the safety, tolerability, PK and immunogenicity of single and multiple ascending doses of MEDI6570 in subjects with Type 2 Diabetes Mellitus Condition or disease Intervention/treatment Phase Atherosclerosis Cardiovascular Disease Biological: MEDI6570 Biological: Placebo Biological: Part B Placebo (...) Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2018 Clinical Trials

32. Assessment of Glucose Concentrations in People Without Diabetes Mellitus After Standardized Meals and in Daily Life

monitoring (CGM) systems. Because current CGM systems typically achieve a lower level of analytical accuracy than BGM systems, participants will perform at least 5 blood glucose (BG) measurements per day. In addition, CGM systems are used to obtain minimally-invasive high-frequency glucose measurements to fill the gaps between BG measurements. Condition or disease Intervention/treatment Phase Subjects Without Diabetes Mellitus Assessment of Glucose Concentrations Device: Blood glucose monitoring system (...) the study site three times. During the first visit, a standardized oral glucose tolerance test will be performed to ensure that participants do not have diabetes mellitus and to obtain glucose concentration data from people without diabetes mellitus during a glucose challenge. On another two days, participants will visit the study site for standardized breakfast and lunch meals to provide glucose concentration data under standardized conditions. Outside of the study site visits, participants are asked

2018 Clinical Trials

33. A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus

participant, not including screening. Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 1 Drug: LY900014 Drug: Insulin Lispro Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 40 participants Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double (Participant, Investigator) Primary Purpose: Basic Science Official Title: Pharmacokinetics and Glucodynamics of LY900014 Compared (...) A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study

2018 Clinical Trials

34. A French Study to Evaluate the Usefulness of Implantable Continuous Glucose Monitoring (CGM) Sensor to Improve Glycemic Control in Participants With Diabetes Mellitus.

the usefulness of using a long term subcutaneously inserted continuous glucose monitoring (CGM) sensor in patients with insulin treated Type 1 or Type 2 Diabetes Mellitus. The study will be conducted in France. Patients will be enrolled into two cohorts and randomized into two groups within each cohorts. Condition or disease Intervention/treatment Phase Diabetes Mellitus Device: Eversense XL Device: Usual SMBG or FGM device used by participants Not Applicable Detailed Description: 324 patients (...) A French Study to Evaluate the Usefulness of Implantable Continuous Glucose Monitoring (CGM) Sensor to Improve Glycemic Control in Participants With Diabetes Mellitus. A French Study to Evaluate the Usefulness of Implantable Continuous Glucose Monitoring (CGM) Sensor to Improve Glycemic Control in Participants With Diabetes Mellitus. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search

2018 Clinical Trials

35. A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus

Party): Eli Lilly and Company Study Details Study Description Go to Brief Summary: Two forms of insulin lispro (LY900014 and Humalog®) and two forms of insulin aspart (NovoRapid® and Fiasp®) will be given to trial participants with diabetes mellitus type 1 by injection under the skin. The study will assess how fast the active ingredient (insulin lispro or insulin aspart) gets into the blood stream and how long it takes the body to remove it. A test meal will be given to trial participants to assess (...) the course of the blood sugar lowering effect of the investigational products. The safety and tolerability of LY900014 will also be assessed. Screening is required within 14 days prior to the lead in. For each participant, the study will last up to 91 days. Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 1 Drug: LY900014 Drug: Insulin Lispro Drug: Insulin Aspart Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual

2018 Clinical Trials

36. A Research Study Looking at How Faster Aspart Injected in Double Concentration Works in the Body of People With Type 1 Diabetes Mellitus

on individual visit schedule. The participant will have nine clinic visits with the study doctor (including the one in which the participant give consent). Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 1 Drug: Faster Aspart 200 U/mL Drug: Faster aspart 100 U/mL Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 56 participants Allocation: Randomized Intervention Model: Crossover Assignment Masking (...) A Research Study Looking at How Faster Aspart Injected in Double Concentration Works in the Body of People With Type 1 Diabetes Mellitus A Research Study Looking at How Faster Aspart Injected in Double Concentration Works in the Body of People With Type 1 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study

2018 Clinical Trials

37. Iontophoresis of Treprostinil to Enhance Wound Healing in Diabetic Foot Skin Ulcers

for MeSH terms Ulcer Diabetic Foot Foot Ulcer Skin Ulcer Pathologic Processes Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Leg Ulcer Skin Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Diabetic Neuropathies Foot Diseases Treprostinil Antihypertensive Agents (...) Iontophoresis of Treprostinil to Enhance Wound Healing in Diabetic Foot Skin Ulcers Iontophoresis of Treprostinil to Enhance Wound Healing in Diabetic Foot Skin Ulcers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before

2018 Clinical Trials

38. Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus

14, 2016 Last Update Posted : September 5, 2017 Sponsor: Lakewood-Amedex Inc Information provided by (Responsible Party): Lakewood-Amedex Inc Study Details Study Description Go to Brief Summary: Phase I/IIa, five cohort ascending dose with two dosing arms per cohort, study in Type I or II diabetes mellitus subjects with a chronic infected diabetic ulcer defined as having a DUSS score of 0 to 3 and DFI wound score of 1 to 3. Condition or disease Intervention/treatment Phase Diabetic Foot (...) relevant MeSH terms: Layout table for MeSH terms Diabetes Mellitus Diabetic Foot Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Foot Ulcer Leg Ulcer Skin Ulcer Skin Diseases Diabetes Complications Diabetic Neuropathies

2016 Clinical Trials

39. Data on medicinal plants used in Central America to manage diabetes and its sequelae (skin conditions, cardiovascular disease, kidney disease, urinary problems and vision loss) (Full text)

Data on medicinal plants used in Central America to manage diabetes and its sequelae (skin conditions, cardiovascular disease, kidney disease, urinary problems and vision loss) The data described in this article is related to the review article "Medicinal plants used in the traditional management of diabetes and its sequelae in Central America: a review" (Giovannini et al., 2016) [1]. We searched publications on the useful plants of Central America in databases and journals by using selected (...) relevant keywords. We then extracted reported uses of medicinal plants within the disease categories: diabetes mellitus, kidney disease, urinary problems, skin diseases and infections, cardiovascular disease, sexual dysfunction, vision loss, and nerve damage. The following countries were included in our definition of Central America: Belize, Guatemala, Honduras, El Salvador, Nicaragua, Costa Rica and Panama. Data were compiled in a bespoke Access database. Plant names from the published sources were

2016 Data in brief PubMed

40. Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus

Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information (...) . Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>